



**Contact:**

Lynne Harris, ASPET  
Director, Marketing  
and Communications

[lharris@aspet.org](mailto:lharris@aspet.org)

301-804-5768 (c)

**October 1, 2024**

**For Immediate Release**

**ASPET Selects John D. Schuetz, PhD, to Lead New *ASPET Discovery* Journal**

ROCKVILLE, MD — ASPET welcomes Dr. John D. Schuetz as the inaugural Editor-in-Chief of the Society's new Gold Open Access journal, *ASPET Discovery*. ASPET's Publications Committee selected Dr. Schuetz after an extensive search. The journal is scheduled to launch January 1, 2025.

Dr. Schuetz attended the University of Minnesota and, while in the honors program, was employed in the laboratory of Travis Thompson, PhD, known as a pioneer of behavioral pharmacology. He subsequently received his PhD from the Medical College of Virginia at Virginia Commonwealth University with Robert Diasio, MD, whose lab identified the genetic basis of dihydropyrimidine dehydrogenase (DPD) enzyme deficiency. Dr. Schuetz conducted postdoctoral training with I. David Goldman, MD, who studied SLC19A gene and folate metabolism. Dr. Schuetz also worked with Philip Guzelian, MD, who identified CYP3, a subfamily of the cytochrome P450 superfamily of genes. At the same institution, Dr. Schuetz identified and cloned CYP3A5 and 7.

Dr. Schuetz joined St. Jude Children's Research Hospital as an Assistant Member (1992-1993). He is a member and former Vice Chair (2005-2022) of the Pharmaceutical Sciences Department (now Department of Pharmacy and Pharmaceutical Sciences). His laboratory employs a variety of sophisticated technologies (super-resolution microscopy, biochemistry, cell biology, proteomics, conditional knockouts, clustered regularly interspaced short palindromic repeats, or CRISPR screens, etc.) to understand how transporters contribute to pathophysiology, drug response, toxicology and metabolism. The lab has defined and functionally "de-orphaned" transporters: ABCB6, ABCG2, and ABCC4 with more than 175 articles in peer-reviewed journals and several patents related to ABC transporters.

Dr. Schuetz currently serves as an Associate Editor for the ASPET journals *Pharmacological Reviews* and *Drug Metabolism and Disposition* and also serves on the editorial boards of other journals. He is an ASPET Fellow (2021), former President of ASPET (2017), ASPET President-elect (2016) and Chair, ASPET Financial Task Force (2016). In addition, he has or is serving in

leadership roles in other scientific societies, including the American Association for the Advancement of Science and the International Transmembrane Transporter Society.

Submissions to *ASPET Discovery* will open in the near future. *ASPET Discovery* will publish bi-monthly and include a range of article types including original research articles and minireviews that address all areas of pharmacology and experimental therapeutics. Dr. Schuetz will serve a three-year term that can be renewed for one additional three-year term.

###

### **About ASPET**

The American Society for Pharmacology and Experimental Therapeutics is an international, 4,000-member scientific society whose members conduct basic and clinical pharmacological research in academia, industry, and the government. Members' research efforts help develop new medicines and therapeutic agents to fight existing and emerging diseases. ASPET supports 10 divisions, each of which is governed by an Executive Committee. ASPET members have access to all journal content. The ASPET office is in Rockville, Md. Visit [aspet.org](http://aspet.org) to learn more.